Destiny Pharma names new non-executive director
Custom Synthesis, Destiny Pharm has consolidate its board with appointing Nick Rodgers as an independent Non-Executive Director with immediate effect.
Rodgers has considerable Board experience in both public and private growth companies, particularly those in the life science sector, as well as a background as a successful corporate financier and investment banker, Destiny said. He is currently chairman of SEHTA, one of the largest health technology networking organisations in the UK. Prior to this, he was non-executive director and then chairman of fully listed Oxford Biomedica plc, a leading gene-based biopharmaceutical company, from 2004 until 2016. Previously. Rodgers headed up both the Life Science and Corporate Finance department at Evolution Beeson Gregory (now Investec) advising many life science listed companies from 1989 until 2003, Destiny Pharma said.
Sir Nigel Rudd, Chairman of Destiny Pharma said: “We are very pleased to announce Nick’s appointment to our Board. His experience of guiding growth companies, and in particular those in the life science sector will be invaluable as Destiny Pharma expands its activities and continues to advance its lead drug candidate, XF-73, through clinical development.”http://www.haihengpharma.com/destiny-pharma-names-new-non-executive-director/News